Cleared Traditional

K893415 - TRANS-ORAL DEPTH GAUGE

K893415 is an FDA 510(k) clearance for TRANS-ORAL DEPTH GAUGE, manufactured by Ruggles Corp.. The device is a Class 1 Orthopedic device with product code LYQ cleared through the Traditional 510(k) pathway after a 36-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1989
Decision
36d
Days
Class 1
Risk

K893415 is an FDA 510(k) clearance for the TRANS-ORAL DEPTH GAUGE. Classified as Accessories, Fixation, Spinal Intervertebral Body (product code LYQ), Class I - General Controls.

Submitted by Ruggles Corp. (No. Quincy, US). The FDA issued a Cleared decision on June 7, 1989 after a review of 36 days - a notably fast clearance cycle.

This device falls under the Orthopedic FDA review panel, regulated under 21 CFR 888.4540 - the FDA orthopedic device regulatory framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Ruggles Corp. devices

FDA 510(k) Submission Details - K893415

510(k) Number K893415 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 02, 1989
Decision Date June 07, 1989
Days to Decision 36 days
Submission Type Traditional
Review Panel Orthopedic (OR)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
86d faster than avg
Panel avg: 122d · This submission: 36d
Pathway characteristics
Predicate-based equivalence.

LYQ Device Classification - Class 1, General Controls

Product Code LYQ Accessories, Fixation, Spinal Intervertebral Body
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 888.4540
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.